Neonc Technologies, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Holding, Subsidiary

Established: 2008-01-01

Employees: 1

Market Cap: -

Website: http://www.neonctech.com

Clinical Trials

A Study of the Safety, Dosing, and Delivery of NEO100 in Patients with Pediatric Brain Tumors

Phase 1

Not yet recruiting

Conditions: Diffuse Midline Glioma, H3 K27M-Mutant
Pediatric Tumor of Brain Stem
Pineocytoma
Spinal Cord Tumor
Pediatric Tumor of Brain
High Grade Glioma
Pediatric Tumor of CNS
Choroid Plexus Carcinoma, Childhood

Interventions: Drug: NEO100

First Posted Date: 2024-04-10

Last Posted Date: 2024-10-14

Lead Sponsor: Neonc Technologies, Inc.

Target Recruit Count: 15

Registration Number: NCT06357377

Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1

Recruiting

Conditions: Glioblastoma, IDH-wildtype
Head and Neck Squamous Cell Carcinoma
Melanoma
Merkel Cell Carcinoma
Mismatch Repair Deficient Solid Malignant Tumor
Microsatellite Instability-High Colorectal Cancer
Colorectal Cancer
Microsatellite Instability-High Solid Malignant Tumor
Non-small Cell Lung Cancer
Renal Cell Carcinoma

Interventions: Drug: NEO212 Oral Capsule
Drug: FOLFIRI Protocol
Drug: Ipilimumab
Drug: Regorafenib
Drug: Pembrolizumab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Bevacizumab
Drug: Nivolumab

First Posted Date: 2023-09-21

Last Posted Date: 2024-10-16

Lead Sponsor: Neonc Technologies, Inc.

Target Recruit Count: 134

Registration Number: NCT06047379

Locations: 🇺🇸
Precision NextGen Oncology, Beverly Hills, California, United States
🇺🇸
Northwest Medical Specialties, Tacoma, Washington, United States

NEO100 and High-Grade Meningioma

Phase 2

Recruiting

Conditions: Residual, Progressive or Recurrent Grade II or III Meningioma

Interventions: Drug: NEO100

First Posted Date: 2021-08-26

Last Posted Date: 2024-10-14

Lead Sponsor: Neonc Technologies, Inc.

Target Recruit Count: 30

Registration Number: NCT05023018

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States

Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

Phase 1

Recruiting

Conditions: Glioblastoma Multiforme

Interventions: Drug: Perillyl alcohol

First Posted Date: 2016-03-10

Last Posted Date: 2024-12-09

Lead Sponsor: Neonc Technologies, Inc.

Target Recruit Count: 49

Registration Number: NCT02704858

Locations: 🇺🇸
Northwell Health, New York, New York, United States
🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸
Atlantic Health (Overlook Medical Center), Summit, New Jersey, United States

and more 5 locations

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy